作者
GK Soppa, J Lee, MA Stagg, S Youssef, CM Terracciano, MH Yacoub
发表日期
2006/2/1
期刊
The Journal of Heart and Lung Transplantation
卷号
25
期号
2
页码范围
S143-S144
出版商
Elsevier
简介
Conclusion: Cost-effectiveness is in favor of everolimus compared to MMF in the management of de novo heart transplant patients. Everolimus may achieve a higher efficacy gain vs. Aza than MMF and has lower incremental drug cost vs. Aza than MMF.
学术搜索中的文章
GK Soppa, J Lee, MA Stagg, S Youssef… - The Journal of Heart and Lung Transplantation, 2006